Trial: 202105154

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens

Phase

II (Cancer Control)

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov